Harvard Law School, J.D., cum laude, 2016; Ames Moot Court Competition winner
University of Alabama, MBA, 2013
Clemson University, B.S., summa cum laude, 2011
Kevin Crandall counsels companies and individuals in all phases of civil litigation. His recent experience covers a broad range of subject matters, including antitrust litigation, unfair trade practices, breaches of fiduciary duties, product liability and class actions. He has represented clients in federal and state court, including the North Carolina Business Court and the Supreme Court of North Carolina.
In addition to his litigation practice, Kevin advises companies on antitrust compliance matters and assists them in obtaining antitrust clearance for significant mergers and acquisitions.
Complex Business Litigation
Represents debtor as special counsel for asbestos claims estimation matters in In re Bestwall LLC, Case No. 17-31795 (Bankr. W.D.N.C.).
Represents debtor as special counsel for asbestos claims estimation matters in In re DBMP LLC, Case No. 20-30080 (Bankr. W.D.N.C.).
Obtained dismissal of claims for conversion, unfair or deceptive trade practices, and breach of fiduciary duty in North Carolina Business Court case against software company.
Represented estate in a wrongful death lawsuit relating to a CO2 paintball canister that exploded and killed a 38-year-old man.
Obtained directed verdict in federal jury trial on behalf of nonprofit employer in case alleging religious discrimination.
Represented former North Carolina Gov. James B. Hunt Jr. and former North Carolina Supreme Court Chief Justice Burley B. Mitchell Jr. as friends of the Supreme Court of North Carolina in Cooper v. Berger.
Obtained dismissal, without discovery, of putative class action filed against national insurance company.
Obtained judgment on the pleadings for national retail company in defense of claims alleging breach of contract, breach of fiduciary duties, and unfair and deceptive trade practices.
Antitrust and Competition
Regularly assists companies in complying with governmental reporting obligations under Hart-Scott-Rodino Act and obtaining antitrust clearance of significant transactions. Representative transactions include:
Represented Fresenius Medical Care in its $2 billion acquisition of NxStage Medical Care, Inc.
Represented Fresenius Medical Care North America in its sale of Sound Inpatient Physicians Holdings LLC to a consortium led by Summit Partners L.P. for $2.15 billion.
Represented EnPro Industries in the sale of its Fairbanks Morse division to an affiliate of Arcline Investment Management for $450 million.
Represented a large insurance company in the review of potential strategic transactions.
Represented Fresenius Medical Care in its acquisition of an equity interest in Humacyte Inc.
News & Events
- Aug. 17, 2023
- Jan. 20, 2023
- Aug. 23, 2022
- Sept. 4, 2019
- Aug. 29, 2019
- Aug. 7, 2019
- Feb. 26, 2019
- Robinson Bradshaw Guides Fresenius Through Antitrust Review of Two Transactions Totaling $2.3 BillionJuly 9, 2018
- May 7, 2018
- Jan. 30, 2018
- Oct. 10, 2016
- Feb. 9, 2021Robinson Bradshaw Publication
- March 26, 2020Robinson Bradshaw Publication
- March 26, 2019Robinson Bradshaw Publication
- April 10, 2017Robinson Bradshaw Publication
- March 2, 2017Class Actions Brief Blog